Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

Exclusion Criteria

• •1. LDL-C greater than 250 mg/dL
• •2. LDL-C less than 70 mg/dL at the screening visit in patients with history of documented CVD
• •3. LDL-C less than 100 mg/dL at the screening visit in patients without history of documented CHD or non-CHD CVD, but with other risk factors
• •4. TG greater than 400 mg/dL
• •5. Homozygous FH (clinically or previous genotyping)
• •6. Currently taking a statin that is not atorvastatin
• •7. Currently taking Ezetimibe (EZE)
• •8. Not on a stable dose of allowable lipid modifying treatments (LMT)